T1	Participants 385 465	66 patients with 43 hematologic and 23 solid malignancies (21 breast carcinomas)
T2	Participants 761 799	Patients with hematologic malignancies
T3	Participants 1463 1505	1 of 10 hematologic patients receiving GLN
